Application of combination of aprepitant and chemotherapeutic drugs to preparation of drugs for treating acute lymphoblastic leukemia

A technology of acute lymphocytes and chemotherapy drugs, which is applied in the field of medicine and can solve the problems of poor chemotherapy effects

Inactive Publication Date: 2021-08-06
ZHEJIANG SCI-TECH UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to deal with the poor effect of chemotherapy on cancer patients, the inventors of the present invention found that the NK-1R antagonist aprepitant and chemotherapy drugs showed synergistic effect in acute lymphoblastic leukemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of aprepitant and chemotherapeutic drugs to preparation of drugs for treating acute lymphoblastic leukemia
  • Application of combination of aprepitant and chemotherapeutic drugs to preparation of drugs for treating acute lymphoblastic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0049] 1. Materials and methods

[0050] 1.1 Cell culture. Nalm6 cells obtained from the Second Affiliated Hospital of Zhejiang University were placed in RIPM 1640 (Life Technologies) at 37°C, 5% CO 2 cultivated in a humid environment. 10% heat-inactivated FBS (fetal bovine serum, Beijing Suo Laibao Technology Co., Ltd.) was added to the medium.

[0051] 1.2 Western blot. A 40 μg protein sample was prepared and electrophoresed on an 8-12% SDS-PAGE gel, followed by electrotransfer to a PVDF membrane. The PVDF membrane was then blocked with 5% bovine serum albumin V (Roche) and 0.1% Tween 20 in TBST solution for 2 hours at room temperature. The membrane was then incubated overnight with primary antibodies specific for the protein of interest, including NK-1R (BS2632), GAPDH (AP0063) from Bioworld Technology (Nanjing, China). Using Tanon 5500 chemiluminescent detection system (Tianneng, Shanghai, China) with BiodlightTM ECL chemiluminescent HRP substrate (Bioworld, Nanjing, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a combination of a neurokinin 1 receptor antagonist namely aprepitant and a chemotherapeutic drug to preparation of a drug for treating acute lymphoblastic leukemia of a subject. Specifically, the invention relates to a method for promoting the cancer chemotherapy sensitivity of the subject, and relates to a pharmaceutical composition for treating the acute lymphocytic leukemia, and the pharmaceutical composition comprises an NK-1R antagonist, a chemotherapeutic drug and an optional pharmaceutically acceptable carrier.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a method for inhibiting cell proliferation in the treatment of acute lymphoblastic leukemia, and a pharmaceutical product containing a neurokinin 1 receptor antagonist and two clinical chemotherapy drugs. Background technique [0002] Acute lymphocytic leukemia (ALL) is the most common type of leukemia in children and adolescents, with more than half (54%) of ALL cases diagnosed in leukemia patients under the age of 20 [1] . The World Health Organization divides acute lymphoblastic leukemia into two categories: B lymphocytic leukemia (B-ALL) and T lymphocytic leukemia (T-ALL). In adults, B-ALL accounts for about 75% of cases, and T- ALL accounts for about 25% of cases [2] . Chemotherapy is still the main clinical treatment for acute lymphoblastic leukemia at present, but chemotherapy has severe side effects, high recurrence rate, and the survival rate drops sharply with age...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5377A61K31/704A61P35/02
CPCA61K31/5377A61K31/704A61P35/02A61K2300/00
Inventor 程旭锐马俊杰洪翔宇王雍付彩云
Owner ZHEJIANG SCI-TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap